The company looks rash for promising Tamarack data at the conference, although at least vobra duo’s safety has improved.

Other projects new to the clinic include Haisco’s USP1 inhibitor and and Avistone’s type II c-MET blocker.

Tamarack data are a 2024 catalyst, so why has MacroGenics brought forward a follow-on molecule?

Projects from the likes of BioNTech, Transgene and Scancell will feature, but still have much to prove.

Data on the group’s lead project, the PD-1 x CTLA-4 bispecific vudalimab, are far from emphatic.

Early activity of JANX007 in prostate cancer sees Janux stock gain 190%.

A rare success for Cabometyx sees a survival benefit, but the control regimen raises questions.